CareDx Will Launch Alloheme Without Capping Volume, With A Field Team Far Short Of 100 Reps
CEO John Hanna says the cell-therapy relapse test launches in the first quarter of 2027, built natively into Epic ordering from the first day.
CareDx will not limit volume on Alloheme, its relapse-monitoring test for cell-therapy patients, before Medicare coverage arrives, CEO John Hanna said on the company's third-quarter earnings call, where the company also reported $139 million in revenue. CareDx, a precision medicine company that sells blood tests for transplant recipients, plans a commercial launch in the first quarter of 2027.
No gating, no army of reps
Asked by a Stephens analyst whether it would gate volume ahead of Medicare coverage, Hanna said no. He believes the test will become standard of care and will significantly change how patients with AML and MDS, two blood cancers, are monitored.
"We're not going to hire 100 people to do this," Hanna said. Instead, a limited field team will target the top stem-cell transplant and bone marrow centers first, a new call point for the company, where hematologist-oncologists manage these patients.
Alloheme will also launch native on Epic Aura, the electronic medical record platform, so Hanna said 100% of ordering should flow through that integration on day one. He called it the first test he is aware of that he has launched natively on the platform.
The road to Medicare coverage
Coverage starts with publication of the Acrobat validation study. Hanna said the steering committee has submitted the manuscript for peer review. At a conference earlier this year, the authors showed Alloheme flagged molecular relapse a median of 41 days before clinical diagnosis.
Second, the company must finish lab readiness work in 2026, which parallels the data needed for New York State Department of Health approval, so it can submit coverage data in 2027. Readiness activities are due to wrap up before year-end.
On the sister kidney product, HistoMap, Hanna said the market is not huge: roughly 2,500 to 5,000 kidney biopsies a year. CareDx will likely target Medicare reimbursement near $3,000 a test, in line with other tissue-based gene expression tests, and plans broader availability in 2027.
A quarter of 39% revenue growth
Chief Financial Officer Keith Kennedy said revenue rose 39% to $139 million, including $15 million of out-of-period revenue. Testing volume climbed 51% to 75,900 tests, and adjusted EBITDA doubled to $30 million from $15 million. CareDx ended the quarter with $250 million in cash and no debt.
It raised full-year revenue guidance by $30 million to $520 million to $530 million, and adjusted EBITDA guidance by $23 million to $90 million to $100 million. Transplant testing volume grew 21%. The company's market value was $3.7 billion at Thursday's close.
The next marker is the first quarter of 2027, when Alloheme is planned to reach the market with its small team and Epic ordering in place.
Sources
- CareDx Non-GAAP EPS of $0.70 beats by $0.44, revenue of $139M beats by $17.04M (NASDAQ:CDNA) | Seeking Alpha — seekingalpha.com
- CareDx: Q3 Earnings Snapshot — Associated Press
- CareDx: Q3 Earnings Snapshot – WTOP News — wtop.com
- CareDx: Q3 Earnings Snapshot | wusa9.com — Associated Press
- CareDx: Q3 Earnings Snapshot | king5.com — Associated Press